TY - JOUR
T1 - Does electronic monitoring influence adherence to medication?
T2 - Randomized controlled trial of measurement reactivity
AU - Sutton, Stephen
AU - Kinmonth, Ann Louise
AU - Hardeman, Wendy
AU - Hughes, Dyfrig
AU - Boase, Sue
AU - Prevost, A. Toby
AU - Kellar, Ian
AU - Graffy, Jonathan
AU - Griffin, Simon
AU - Farmer, Andrew
PY - 2014/12
Y1 - 2014/12
N2 - Background: Electronic monitoring is recommended for accurate measurement of medication adherence but a possible limitation is that it may influence adherence. Purpose: To test the reactive effect of electronic monitoring in a randomized controlled trial. Methods: A total of 226 adults with type 2 diabetes and HbA1c ≥58 mmol/mol were randomized to receiving their main oral glucose lowering medication in electronic containers or standard packaging. The primary outcomes were self-reported adherence measured with the MARS (Medication Adherence Report Scale; range 5-25) and HbA1c at 8 weeks. Results: Non-significantly higher adherence and lower HbA1c were observed in the electronic container group (differences in means, adjusting for baseline value: MARS, 0.4 [95 % CI -0.1 to 0.8, p = 0.11]; HbA1c (mmol/mol), -1.02 [-2.73 to 0.71, p = 0.25]). Conclusions: Electronic containers may lead to a small increase in adherence but this potential limitation is outweighed by their advantages. Our findings support electronic monitoring as the method of choice in research on medication adherence. (Trial registration Current Controlled Trials ISRCT N30522359)
AB - Background: Electronic monitoring is recommended for accurate measurement of medication adherence but a possible limitation is that it may influence adherence. Purpose: To test the reactive effect of electronic monitoring in a randomized controlled trial. Methods: A total of 226 adults with type 2 diabetes and HbA1c ≥58 mmol/mol were randomized to receiving their main oral glucose lowering medication in electronic containers or standard packaging. The primary outcomes were self-reported adherence measured with the MARS (Medication Adherence Report Scale; range 5-25) and HbA1c at 8 weeks. Results: Non-significantly higher adherence and lower HbA1c were observed in the electronic container group (differences in means, adjusting for baseline value: MARS, 0.4 [95 % CI -0.1 to 0.8, p = 0.11]; HbA1c (mmol/mol), -1.02 [-2.73 to 0.71, p = 0.25]). Conclusions: Electronic containers may lead to a small increase in adherence but this potential limitation is outweighed by their advantages. Our findings support electronic monitoring as the method of choice in research on medication adherence. (Trial registration Current Controlled Trials ISRCT N30522359)
KW - Diabetes
KW - Electronic monitoring
KW - Measurement reactivity
KW - Medication adherence
UR - http://www.scopus.com/inward/record.url?scp=84894247087&partnerID=8YFLogxK
U2 - 10.1007/s12160-014-9595-x
DO - 10.1007/s12160-014-9595-x
M3 - Article
AN - SCOPUS:84894247087
SN - 0883-6612
VL - 48
SP - 293
EP - 299
JO - Annals of Behavioral Medicine
JF - Annals of Behavioral Medicine
IS - 3
ER -